Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Adlai Nortye
View:
Post by pelaboost on Sep 30, 2023 12:06pm

Adlai Nortye

@Noteable.

I was looking through the AN website and it went down; not sure why. Anyway I did notice they have mentioned PDAC in relation to pelareorep under Science & Pipeline. My point being they have not erased ONCY from their website and presumably will run a Phase 3 mBC trial without a CPI. It is intended for Chinese patients. CPIs are very expensive and that is possibly one of the reasons why PanCAN will also try with and without a CPI.

I agree with your sentiments on opacity et al.  It has been a tortuous journey.
I did add a small amount yesterday, and as a retiree I do not have the loose readies of many here; so I do think we are gathering steam. Perhaps the poster on SW can put up Rubeus Hagrid again; that gave  me a good laugh and has now been included as number four on the ONCY humor list.

Cheers



Comment by pelaboost on Sep 30, 2023 2:07pm
I got more curious about the AN Phase 3 Bridging Study, and found the following. Search: Innovation drug approvals based on a bridging study: from concept to practice. I am not making any assertions, but did find this interesting.
Comment by Buckhenry on Sep 30, 2023 3:17pm
Unnoteable finally almost said something worthwhile... they need to better manage... I would change the word manage to lead. Managers delegate and blame others while leaders lead by example and take responsibility. 
Comment by Azzak34 on Sep 30, 2023 3:30pm
That's deep stuff Bucky. You been reading them books on personal responsibility? 
Comment by Buckhenry on Sep 30, 2023 3:42pm
No assak... I write them... but you have to get out of the children's section  to find them. Course you would need an adult to read them to you and even then you could not comprehend. I will put more pictures in my next book for you. 
Comment by Azzak34 on Sep 30, 2023 3:46pm
Bahahaha. You are an inspiration!! What does a little weasel, zilch like you know about leading? Hahaha what an idiot. 
Comment by 2O2Ovision on Sep 30, 2023 4:32pm
@pelaboost. If you want a fairly detailed and updated picture of AN, have a look at the F1 form they just filed with the SEC for their IPO. Pela or AN1004 is mentioned a few times (p.137 of latest amended F1 is a good one). They clearly haven't moved on but rather are probably focusing on otther things while ONC sorts out their laundry. I can only assume there is something in the contract that ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities